India’s medical device sector is gradually transitioning from a cost-driven manufacturing base to an innovation-oriented ecosystem. Despite being one of the fastest-growing healthcare markets, the country still depends heavily on imports for advanced medical technologies, particularly in high-risk and critical care segments. This imbalance highlights a persistent gap between clinical demand and indigenous technological capability.1
The development of medical devices is inherently complex, involving iterative design processes, regulatory compliance, risk assessment, and clinical validation, all of which can slow innovation, especially in low- and middle-income settings.1 Despite this, a growing number of Indian manufacturers are rethinking this pathway, developing solutions that are not only cost-effective but also closely aligned with the practical realities of healthcare delivery.
For a long time, most Indian manufacturers focused on producing basic medical supplies and low-risk equipment, while more advanced and complex devices were largely dominated by multinational companies. Recent trends, however, suggest a shift toward:
Artificial intelligence–enabled devices
Point-of-care and decentralized diagnostics
Affordable critical care technologies
Devices tailored for resource-limited settings
Emerging research also emphasizes the growing role of digital health integration, wearable monitoring, and AI-driven diagnostics, which are expected to reshape healthcare delivery globally.
This transition is not merely technological, it reflects a broader shift toward accessible, patient-centered healthcare systems.2,3
Here are some of the emerging companies contributing to this shift in India’s medical device landscape.
Noccarc represents a new wave of Indian companies developing high-acuity critical care systems, including ventilators and digital ICU platforms.
Its approach integrates:
ICU ventilators designed for diverse hospital settings
Real-time monitoring systems
Cloud-based ICU management platforms
By combining hardware innovation with digital integration, the company addresses a critical gap in India’s healthcare system, affordable and scalable intensive care infrastructure.
From a systems perspective, such innovations align with global trends toward connected healthcare environments, where real-time data enhances clinical decision-making.
BioSense Technologies focuses on decentralizing diagnostics through portable and user-friendly medical devices.
Its innovations emphasize:
Smartphone-integrated diagnostic tools
Rapid testing solutions for primary care
Devices designed for rural and underserved populations
The shift toward point-of-care testing (POCT) is particularly significant in India, where access to centralized laboratories remains uneven.
Studies indicate that decentralized diagnostics can significantly improve early disease detection and management, especially for chronic conditions.3
BioSense exemplifies how technology can bridge infrastructure gaps in healthcare delivery.
Sensa Core Medical Instrumentation Pvt. Ltd. operates in the field of in-vitro diagnostics (IVD) and has built a strong presence in both domestic and international markets.
Its product range includes:
Electrolyte analyzers
Blood gas analyzers
Glucose and lactate monitoring systems
These technologies are essential in critical care, emergency medicine, and routine laboratory diagnostics. The company’s focus on affordability and local manufacturing contributes to reducing dependence on imported diagnostic equipment.
In a broader context, strengthening diagnostic infrastructure is key to improving clinical outcomes and healthcare system efficiency.
InnAccel Technologies adopts a biodesign-driven approach, focusing on identifying unmet clinical needs before developing solutions.
Key areas of innovation include:
Neonatal respiratory support systems (SAANS)
AI-based fetal monitoring devices (Fetal Lite)
Infection control technologies for critical care (VapCare)
This model reflects a growing emphasis on frugal innovation, where products are designed to be both cost-effective and clinically relevant.
Research supports that such approaches are essential for sustainable healthcare innovation in emerging economies.2
InnAccel demonstrates how structured innovation frameworks can translate into high-impact, scalable medical technologies.
Axio Biosolutions focuses on developing biomaterial-based solutions, particularly for wound care and hemorrhage management.
Its work centers around chitosan-based products, designed to support rapid bleeding control in trauma and surgical settings. These solutions are intended to be easy to use, fast-acting, and suitable for both hospital and field use, which is especially relevant in emergency care scenarios.
Rather than relying on complex machinery, Axio’s approach highlights how material science can offer practical, life-saving interventions. This is particularly important in settings where immediate access to advanced infrastructure may not be available.
Perfint Healthcare operates in the domain of image-guided interventions, combining imaging with advanced procedural planning tools.
The company is known for platforms such as:
MAXIO, which assists in planning and guiding CT-based interventions
ROBIO, a robotic positioning system designed to support procedural accuracy
These technologies are used in procedures like tumor biopsies, ablations, and targeted therapies, where precision is critical. By enabling better visualization and planning, they help clinicians perform minimally invasive interventions with greater consistency.
Cardiac Design Labs focuses on cardiac diagnostics through wearable technology and digital platforms.
Its solutions aim to make heart monitoring more:
Continuous rather than episodic
Accessible outside hospital settings
Integrated with remote healthcare systems
By enabling long-term ECG monitoring and digital data sharing, such technologies support earlier detection of cardiac abnormalities and improve follow-up care. This is particularly relevant in a country like India, where cardiovascular disease remains a major health burden.
BrainSightAI is working at the intersection of neuroscience and artificial intelligence, with a focus on brain imaging and connectomics.
Its platform uses advanced data analysis to map functional brain networks, which may assist in:
Neurosurgical planning
Understanding neurological disorders
Supporting rehabilitation strategies
By moving beyond traditional imaging interpretation, BrainSightAI aims to provide more detailed, patient-specific insights into brain function.
Research1 highlights that successful medical device innovation requires:
Clear identification of clinical needs
Iterative prototyping and testing
Regulatory and quality compliance
Continuous performance evaluation
The companies discussed here reflect these principles in practice by:
Designing solutions for real-world constraints
Integrating digital technologies into traditional devices
Prioritizing affordability without compromising quality
Additionally, advancements in remote monitoring and wearable technologies underscore the growing importance of continuous, decentralized healthcare delivery systems.3
Despite promising progress, several barriers continue to limit growth:
Regulatory complexity and approval timelines
Limited funding for research and development
Dependence on imported components
Low global brand visibility compared to multinational corporations
Addressing these challenges will require policy support, increased investment, and stronger collaboration between academia and industry.
While large multinational corporations continue to dominate the Indian medical device market, it is the emerging and often overlooked domestic manufacturers that are driving meaningful, context-specific innovation.
By focusing on accessibility, affordability, and real-world clinical needs, these companies are not only transforming healthcare delivery in India but also creating scalable solutions for other low- and middle-income countries.
1. Marešová, Petra, Blanka Klímová, Jan Honegr, Kamil Kuča, Wan Nor H. Ibrahim, and Ali Selamat. 2020. “Medical Device Development Process, and Associated Risks and Legislative Aspects—Systematic Review.” Frontiers in Public Health 8: 308.
2. Amaral, Carolina, Maria Paiva, Ana Rita Rodrigues, Francisco Veiga, and Victoria Bell. 2024. "Global Regulatory Challenges for Medical Devices: Impact on Innovation and Market Access" Applied Sciences 14, no. 20: 9304.
3. Nolan, Niamh, and Olivia McDermott. 2025. “Failure Mode Effect Analysis Use and Limitations in Medical Device Risk Management.” Journal of Open Innovation: Technology, Market, and Complexity 11 (1): 100439.
